These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 715807)

  • 1. [Generic symptoms of Hodgkin's disease in relation to other prognostic criteries (author's transl)].
    Pemsel HK; Jacobs C; Hess F; Kalbfleisch H
    Strahlentherapie; 1978 Nov; 154(11):758-65. PubMed ID: 715807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
    Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
    Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hodgkin's disease, stage IVb: survival for 12 years (author's transl)].
    Schirmeister J; Krieger G
    Med Klin; 1977 Apr; 72(15):637-41. PubMed ID: 853978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic factors concerning the survival time of Hodgkin's disease stage III and IV, treated with cytostatic agents].
    Stoller U; Brunner K
    Schweiz Med Wochenschr; 1976 Apr; 106(15):507-13. PubMed ID: 982004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrelationship between several prognostic factors in Hodgkin's disease.
    Kotlarek-Haus S; Gabryś K; Starzyk H; Sciborski R; Gałazka Z
    Arch Geschwulstforsch; 1982; 52(4):293-301. PubMed ID: 7138241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic models for Hodgkin's disease].
    Panyshin GA; Datsenko PV; Sotnikov VM; Mel'nik IuD
    Vopr Onkol; 2006; 52(5):538-43. PubMed ID: 17168362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late relapse after treatment for clinical stage I and II Hodgkin's disease.
    Brierley JD; Rathmell AJ; Gospodarowicz MK; Sutcliffe SB; Pintillie M
    Cancer; 1997 Apr; 79(7):1422-7. PubMed ID: 9083165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin's disease and age.
    Specht L; Nissen NI
    Eur J Haematol; 1989 Aug; 43(2):127-35. PubMed ID: 2792320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease.
    Yildiz F; Zengin N; Engin H; Güllü I; Barista I; Caglar M; Ozyar E; Cengiz M; Gürkaynak M; Zorlu F; Caner B; Atahan IL; Tekuzman G
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):839-46. PubMed ID: 15465201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hodgkin's disease. Results from a program in radiation therapy.
    Micaily B; Brady LW
    Am J Clin Oncol; 1984 Apr; 7(2):159-71. PubMed ID: 6422736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost determinants in aggressive non-Hodgkin's lymphoma.
    van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
    Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical aspects and therapy of stage III Hodgkin's disease (author's transl)].
    Weh HJ; Andrieu JM
    MMW Munch Med Wochenschr; 1980 Jun; 122(25):932-4. PubMed ID: 6772941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy.
    Smith RS; Chen Q; Hudson MM; Link MP; Kun L; Weinstein H; Billett A; Marcus KJ; Tarbell NJ; Donaldson SS
    J Clin Oncol; 2003 May; 21(10):2026-33. PubMed ID: 12743158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic significance of the lung lesions in lymphogranulomatosis].
    Simbirtseva LP; Gubareva AV; Sheĭdakov AA; Skripkina NS
    Vopr Onkol; 1984; 30(2):40-5. PubMed ID: 6702130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Autoimmune haemolytic anaemia associated with Hodgkin's disease. Characteristics, prognosis and incidence (author's transl)].
    Andrieu JM; Youinou P; Marcelli A
    Nouv Presse Med; 1981 Oct; 10(36):2951-4. PubMed ID: 7290949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hodgkin's disease: a retrospective analysis of 15 years experience at a large referral centre.
    Chandi L; Kumar L; Kochupillai V; Dawar R; Singh R
    Natl Med J India; 1998; 11(5):212-7. PubMed ID: 10997167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sites of relapse in Hodgkin's disease with bone marrow involvement treated by multiagent-chemotherapy (author's transl)].
    Andrieu JM; Cramer P; Auclerc G; Teillet F
    Bull Cancer; 1978; 65(3):363-4. PubMed ID: 719189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.